Caribou Biosciences (CRBU) Expected to Announce Earnings on Monday

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) will likely be releasing its earnings data before the market opens on Monday, March 10th. Analysts expect Caribou Biosciences to post earnings of ($0.40) per share for the quarter.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock traded up $0.01 on Thursday, hitting $1.16. The stock had a trading volume of 693,461 shares, compared to its average volume of 1,658,045. The stock has a 50 day moving average of $1.44 and a 200 day moving average of $1.82. The firm has a market capitalization of $105.04 million, a P/E ratio of -0.70 and a beta of 2.31. Caribou Biosciences has a twelve month low of $1.01 and a twelve month high of $7.74.

Analyst Ratings Changes

CRBU has been the subject of several recent research reports. Citigroup decreased their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, November 26th. Bank of America decreased their price objective on Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $10.33.

Remove Ads

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.